NCT04157127 - Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions

Pancreatic AdenocarcinomaPancreatic CancerPancreatic Adenosquamous Carcinoma

Interventions

BIOLOGICAL

Autologous DC Therapy

Trial Locations (3)

RECRUITING

Baylor College of Medicine Medical Center - McNair Campus, Houston

RECRUITING

Baylor St. Lukes Medical Center, Houston

RECRUITING

Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston